Founded in 2023 by George Ueda, PhD and Jamie Lazarovits PhD, Archon Biosciences combines off-the-shelf antibodies with de novo designed nanoparticles that impart robust functional features creating more effective medicines. Archon is improving the immune modulation and super agonism of the TNF receptor superfamily by increasing size and valency of an off-the-shelf antibody to induce significantly stronger responses. The company plans to rescue exiting antibodies that have failed clinical trials due to efficacy and to develop an internal pipeline of drug candidates.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.10.2024 | Seed | $20M | - |
Mentions in press and media 2
| Date | Title | Description |
| 30.10.2024 | Archon Biosciences Raises $20M in Seed Funding | Archon, a Seattle, WA-based biotechnology company providing computationally designed Antibody Cages (AbCs), raised $20M in Seed funding.
The round was led by Madrona Ventures with participation from DUMAC Inc., Sahsen Ventures, WRF Capital,... |
| - | Archon Biosciences | “Archon Bio” |
Reviews 0
